Skip to main navigation Skip to search Skip to main content

Anti-obesity drug discovery: advances and challenges

  • Helmholtz Zentrum München German Research Center for Environmental Health
  • German Centre for Diabetes Research (DZD)
  • University Hospital Leipzig
  • Indiana University Bloomington

Research output: Contribution to journalReview articlepeer-review

844 Scopus citations

Abstract

Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut–brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.

Original languageEnglish
Pages (from-to)201-223
Number of pages23
JournalNature Reviews Drug Discovery
Volume21
Issue number3
DOIs
StatePublished - Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Anti-obesity drug discovery: advances and challenges'. Together they form a unique fingerprint.

Cite this